Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Alaunos Therapeutics Inc.

    NASDAQ: TCRT · Real-Time Price · USD
    4.69
    -0.16 (-3.30%)
    At close: Jul 01, 2025, 3:55 PM

    Alaunos Therapeutics Statistics

    Share Statistics

    Alaunos Therapeutics has 1.64M shares outstanding. The number of shares has increased by 2.39% in one year.

    Shares Outstanding

    n/a
    		 1.64M

    Shares Change (YoY)

    n/a
    		 2.39%

    Shares Change (QoQ)

    n/a
    		 2.39%

    Owned by Institutions (%)

    n/a
    		 0%

    Shares Floating

    n/a
    		 1.27M

    Failed to Deliver (FTD) Shares

    n/a
    		 523

    FTD / Avg. Volume

    n/a
    		 0.1%

    Short Selling Information

    The latest short interest is 38.51K, so 2.35% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 38.51K

    Short % of Shares Out

    n/a
    		 2.35%

    Short % of Float

    n/a
    		 2.49%

    Short Ratio (days to cover)

    n/a
    		 2

    Valuation Ratios

    The PE ratio is -0.65 and the forward PE ratio is -0.25. Alaunos Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.65

    Forward PE

    n/a
    		 -0.25

    PS Ratio

    n/a
    		 305.84

    Forward PS

    n/a
    		 0

    PB Ratio

    n/a
    		 1.48

    P/FCF Ratio

    n/a
    		 -0.62

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Alaunos Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 3.98

    Quick Ratio

    n/a
    		 3.98

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $10,000

    Profits Per Employee

    n/a
    		 $-4,679,000

    Employee Count

    n/a
    		 1

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -25.35% in the last 52 weeks. The beta is -1.09, so Alaunos Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -1.09

    52-Week Price Change

    n/a
    		 -25.35%

    50-Day Moving Average

    n/a
    		 3.05

    200-Day Moving Average

    n/a
    		 2.34

    Relative Strength Index (RSI)

    n/a
    		 70

    Average Volume (20 Days)

    n/a
    		 500,814

    Income Statement

    In the last 12 months, Alaunos Therapeutics had revenue of 10K and earned -4.68M in profits. Earnings per share was -2.92.

    Revenue

    n/a
    		 10K

    Gross Profit

    n/a
    		 10K

    Operating Income

    n/a
    		 -4.81M

    Net Income

    n/a
    		 -4.68M

    EBITDA

    n/a
    		 -4.68M

    EBIT

    n/a
    		 -4.68M

    Earnings Per Share (EPS)

    n/a
    		 -2.92
    Full Income Statement

    Balance Sheet

    The company has 1.09M in cash and 0 in debt, giving a net cash position of 1.09M.

    Cash & Cash Equivalents

    n/a
    		 1.09M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -920.45M

    Total Assets

    n/a
    		 2.12M

    Working Capital

    n/a
    		 5K
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -4.97M and capital expenditures 0, giving a free cash flow of -4.97M.

    Operating Cash Flow

    n/a
    		 -4.97M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -4.97M

    FCF Per Share

    n/a
    		 -3.1
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -48120% and -46790%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -48120%

    Pretax Margin

    n/a
    		 -46790%

    Profit Margin

    n/a
    		 -46790%

    EBITDA Margin

    n/a
    		 -46770%

    EBIT Margin

    n/a
    		 -48120%

    FCF Margin

    n/a
    		 -49710%

    Dividends & Yields

    TCRT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for TCRT.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jul 18, 2024. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Jul 18, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -612.66

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist